GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1Results posted

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Dose of HM15211(Efocipegtrutide) in Healthy Obese Subjects

Lead sponsor

Hanmi Pharmaceutical Company Limited

Asset

Efocipegtrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers, Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Treatment-emergent AEs (any)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03374241

Org study IDHM-TRIA-101

Timeline

Milestones

Study first posted2017-12-15actual

Study start2018-04-04actual

Primary completion2018-09-14actual

Study completion2018-09-14actual

Results first posted2024-05-17actual

Last update posted2025-02-06actual

Assets

Investigational agents

Efocipegtrutide

Study populations

Who this study enrolls

Healthy volunteersObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Female subjects must be non-pregnant and non-lactating

Exclusion criteria

•Participation in an investigational study within 30 days prior to dosing

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Number of Participants With Adverse Events

Time frame:1 month

Treatment-emergent AEs (any)

event count, event

Posted result

Group	Value (count_of_participants), Participants	95% CI
Cohort 1 Active	3	—
Cohort 2 Active	2	—
Cohort 3 Active	3	—
Cohort 4 Active	7	—
Cohort 5 Active	4	—
Placebo	7	—

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.